Fresenius Invests to Help Humacyte Develop Implantable Blood Vessels
Fresenius has invested an additional $25 million in Humacyte Inc, to help the implantable vessel company get market approval. The new vessels, which can be used to create and repair vascular accesses, are now being tested in a clinical trial for use in dialysis.
Read the full article » | Posted 09-14-2021
Related Articles
- Baxter Announces Multiple Online Training Videos for Professionals Posted 04-12-2024
- Humana and Strive Health Expand Holistic Partnership to more Humana Members Posted 04-12-2024
- ASN and Home Dialysis University Collaboration to Increase Home Dialysis Posted 04-12-2024
- Telemedicine Can Help Grow Home Dialysis, Reduce Dropout, and Improve Outcomes Posted 03-15-2024